IMAX To Offer $220M In Convertible Senior Notes Due 2030; $30M Upsize Option Included

• Opportunistic capital raise for the partial refinancing of outstanding 2026 notes, working capital, share repurchases or other general corporate purposes
• IMAX to purchase capped calls intended to offset any share dilution until at least a targeted 75% premium to the last reported sale price of IMAX's common shares on the date of pricing

IMAX Corporation (NYSE:IMAX) ("IMAX") today announced its intention to offer, subject to market and other conditions, $220,000,000 aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and pursuant to exemptions from the prospectus requirements of applicable Canadian securities laws. IMAX also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 calendar days from, and including, the date the notes are first issued, up to an additional $30,000,000 principal amount of notes.

The notes will be senior unsecured obligations of IMAX, will accrue interest payable semi-annually in arrears and will mature on November 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. IMAX will settle conversions in cash or a combination of cash and IMAX's common shares at its election. The notes will be redeemable, in whole or in part, for cash at IMAX's option at any time, and from time to time, on or after November 20, 2028 and on or before the 31st scheduled trading day immediately before the maturity date, but only if the last reported sale price per common share exceeds 130% of the conversion price for a specified period of time. In addition, the notes will be redeemable, in whole and not in part, at IMAX's option at any time in connection with certain changes in tax law. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

IMAX intends to use a portion of the net proceeds from this offering, together with cash on hand and borrowings under its revolving credit facility, to fund the cost of entering into the capped call transactions described below and to consummate the 2026 Notes Repurchases (as defined below). IMAX intends to use any remaining net proceeds from the offering of the notes for working capital, share repurchases or other general corporate purposes, including potentially to repurchase or otherwise retire IMAX's remaining 0.500% Convertible Senior Notes due 2026 (the "2026 notes"), whether in privately negotiated transactions, at maturity or otherwise. If the initial purchasers exercise their option to purchase additional notes, then IMAX intends to use additional cash on hand and/or borrowings under its revolving credit facility to fund the cost of entering into additional capped call transactions.

In connection with this offering, IMAX expects to enter into one or more privately negotiated transactions with one or more holders of the 2026 notes (each, a "2026 Notes Repurchase"), effected through one of the initial purchasers of the notes or its affiliate, as its agent, to repurchase for cash a portion of the 2026 notes. The terms of each 2026 Notes Repurchase will depend on a variety of factors, including the market price of IMAX's common shares and the trading price of the 2026 notes at the time of the 2026 Notes Repurchases. No assurance can be given as to how much, if any, of the 2026 Notes will be repurchased or the terms on which they will be repurchased. This press release is not an offer to repurchase the 2026 notes, and the offering of the notes is not contingent upon the repurchase of the 2026 notes.

In connection with any 2026 Notes Repurchase, IMAX expects that holders of the 2026 notes who agree to have their 2026 notes repurchased and who have hedged their equity price risk with respect to such 2026 notes (the "hedged holders") will unwind all or part of their hedge positions by buying IMAX's common shares and/or entering into or unwinding various derivative transactions with respect to IMAX's common shares. The amount of IMAX's common shares to be purchased by the hedged holders or in connection with such derivative transactions may be substantial in relation to the historical average daily trading volume of IMAX's common shares. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of IMAX's common shares, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes.

In connection with issuing the 2026 notes, IMAX entered into capped call transactions (the "existing capped call transactions") with certain financial institutions (the "existing option counterparties"). If IMAX repurchases any of the 2026 notes, then IMAX intends to enter into agreements with the existing option counterparties on or shortly after the pricing date of this offering to terminate a portion of the existing capped call transactions in a notional amount corresponding to the principal amount of the 2026 notes repurchased. In connection with such terminations and related unwinding of the existing hedge position of the existing option counterparties with respect to such transactions, IMAX expect such existing option counterparties and/or their respective affiliates may sell shares of IMAX's common shares in the open market and/or enter into or unwind various derivative transactions with respect to IMAX's common shares on or shortly after the pricing date of this offering. This activity could affect the market price of IMAX's common shares and the notes.

The 2026 Notes Repurchase and the unwind of the existing capped call transactions described above, and the potential related market activities by the hedged holders and the existing option counterparties, as applicable, could increase (or reduce the size of any decrease in) or decrease (or reduce the size of any increase in) the market price of IMAX's common shares, which may affect the trading price of the notes offered hereby at that time and the initial conversion price of the notes. IMAX cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or IMAX's common shares, and the corresponding effect on the initial conversion price of the notes.

In connection with the pricing of the notes, IMAX expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates and/or other financial institutions (the "option counterparties"). The capped call transactions are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of IMAX's common shares underlying the notes. If the initial purchasers exercise their option to purchase additional notes, IMAX expects to enter into additional capped call transactions with the option counterparties.

The capped call transactions are expected generally to reduce the potential dilution to IMAX's common shares upon any conversion of the notes and/or offset any potential cash payments IMAX is required to make in excess of the principal amount of converted notes, as the case may be, upon conversion of the notes. If, however, the market price per common share, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to IMAX's common shares and/or purchase common shares concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of IMAX's common shares or the notes at that time.

In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to IMAX's common shares and/or purchasing or selling IMAX's common shares or other securities in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes, or following any repurchase, redemption or early conversion of notes). This activity could also cause or avoid an increase or decrease in the market price of IMAX's common shares or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares, if any, and value of the consideration that noteholders will receive upon conversion of the notes.